Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up

• Hauptverfasser: Antonio Lacquaniti (Verfasst von), Patrizio Pasqualetti (Verfasst von), Teresa Casuscelli di Tocco (Verfasst von), Susanna Campo (Verfasst von), Stefania Rovito (Verfasst von), Maurizio Bucca (Verfasst von), Antonino Ragusa (Verfasst von), Paolo Monardo (Verfasst von)
• Format: Buch
• Veröffentlicht: The Korean Society of Nephrology, 2020-09-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Background : : Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have...